Omkar Marathe, MD, of The Oncology Institute of Hope and Innovation Selected for 40 Under 40 in Cancer Award

Award recognizes the contributions made by the nation’s most promising oncology professionals under the age of 40

CERRITOS, Calif.--(BUSINESS WIRE)--The Oncology Institute of Hope and Innovation (TOI) is proud to announce that Omkar Marathe, MD, a TOI physician, has received the “40 Under 40 in Cancer” award.

The 40 Under 40 in Cancer award celebrates the contributions of emerging leaders in cancer care under the age of 40. The award’s sponsors include the Association for Value-Based Cancer Care.

Dr. Marathe treats patients with cancer and blood disorders in the greater Long Beach Area and has received a teaching award for his work with the St. Mary’s Internal Medicine residency program. He has conducted research and published papers in various disciplines of oncology including ocular melanoma and HER2+ breast cancer and was recently named Director for TOI’s highly esteemed clinical trials program. Dr. Marathe is fluent in English, Spanish, Marathi, and conversational Hindi.

Brad Hively, TOI’s CEO, commented: “All of us at The Oncology Institute are incredibly proud of our colleague Dr. Marathe for being selected for this award. He represents what’s best about our company: a dedicated and talented clinician providing innovative and compassionate cancer care to our patients.”

About The Oncology Institute of Hope and Innovation

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is one of the largest community oncology practices in the US as well as our nation’s leading value-based oncology services platform. TOI employs 75 physicians and mid-level practitioners in 42 clinic locations, with more than 500 total employees helping to offer leading-edge, evidence-based cancer care to a population of more than 1.5 million patients. TOI brings comprehensive, integrated cancer care into community settings, including clinical trials, palliative care programs, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced tertiary care settings. For more information visit www.theoncologyinstitute.com.